α-synuclein in the inner retina in parkinson disease

Annals of Neurology

Volumn 75, Issue 6, 2014, Pages 964-966

  Bodis Wollner, Ivan ^a,b   Kozlowski, Piotr B ^c,d   Glazman, Sofya ^a   Miri, Shahnaz ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b SUNY EYE INSTITUTE   (United States)

^c NEUROMEDLAB   (United States)

^d TOURO COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; AUTOPSY; CASE REPORT; CONTROLLED STUDY; DENDRITE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LEWY BODY; NERVE FIBER; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA GANGLION CELL; RETINA INNER PLEXIFORM LAYER; RETINA NERVE CELL; RETINA ROD; VISUAL IMPAIRMENT;

ALPHA-SYNUCLEIN; FEMALE; HUMANS; MALE; PARKINSON DISEASE; RETINA;

EID: 84903711793     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24182     Document Type: Article

References (20)

1. Alafuzoff I, Parkkinen L,. Staged pathology in Parkinson disease. Parkinsonism Relat Disord 2014; 20 (suppl 1): S57-S61.
2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
3. Chaudhuri KR, Schapira AH,. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
4. Bodis-Wollner I,. Foveal vision is impaired in Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 1-14.
5. Bodis-Wollner I,. Retinopathy in Parkinson disease. J Neural Transm 2009; 116: 1493-1501.
6. Spund B, Ding Y, Liu T, et al. Remodeling of the fovea in Parkinson disease. J Neural Transm 2013; 120: 745-753.
7. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009; 127: 737-741.
8. Lee JY, Kim JM, Ahn J, et al. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's disease. Mov Disord 2014; 29: 61-67.
9. Ho CY, Troncoso JC, Knox D, et al. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol 2014; 24: 25-32.
10. Kozlowski PB, Commins DL, Valdes-Sueiras M, et al. Alzheimer disease (AD) type changes in AIDS. FASEB J 2007; 21: 560.3.
11. Witkovsky P,. Dopamine and retinal function. Doc Ophthalmol 2004; 108: 17-39.
12. Leger F, Fernagut PO, Canron MH, et al. Protein aggregation in the aging retina. J Neuropathol Exp Neurol 2011; 70: 63-68.
13. Surguchov A, McMahan B, Masliah E, Surgucheva I,. Synucleins in ocular tissues. J Neurosci Res 2001; 65: 68-77.
14. Maurage CA, Ruchoux MM, de Vos R, et al. Retinal involvement in dementia with Lewy bodies: a clue to hallucination? Ann Neurol 2003; 54: 542-547.
15. Kramer ML, Schulz-Schaeffer WJ,. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-1410.
16. Li YH, Gao N, Ye YW, et al. Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase. Acta Neurol Belg 2011; 111: 130-135.
17. Peng X, Tehranian R, Dietrich P, et al. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005; 118 (pt 15): 3523-3530.
18. George S, Rey NL, Reichenbach N, et al. α-Synuclein: the long distance runner. Brain Pathol 2013; 23: 350-357.
19. Freundt EC, Maynard N, Clancy EK, et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol 2012; 72: 517-524.
20. Bodis-Wollner I,. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990; 13: 296-302.